ISSN: 2348-6295

Journal of Pharma Creations (JPC)

JPC |Vol.12 | Issue 2 | Apr - Jun -2025

www.pharmacreations.com

DOI : https://doi.org/10.61096/jpc.v12.iss2.2025.93-103

Research

Formulation, Optimization And Evaluation Of Mebendazole Orodispersible Tablets Utilising Natural Polymers

Gajjala Supraja*, T. Sowmya[1], K. Tharun kumar[2], Dr. T. Mangilal[3], Afreen Banu[4]

Smt.Sarojini Ramulamma College Of Pharmacy, Seshadrinagar, Mahabubnagar, Telangana – 509 001, India

*Author for Correspondence: Gajjala Supraja
Email: teelavath@gmail.com

Published on: 08 Mar 2025

Published by:
DrSriram Publications

Abstract

Oral dispersible tablets (ODTs) are patient friendly dosage form that rapidly disintegrant or dispersed in mouth without the need of water. In the present investigation eight ODT formulations of mebendazole, an antiretroviral drug, were prepared using different superdisintegrants Oral dispersible tablets (ODTs) are patient friendly dosage form that rapidly disintegrant or dispersed in mouth without the need of water. In the present investigation eight ODT formulations of mebendazole, an antiretroviral drug, were prepared using different superdisintegrants Oral dispersible tablets (ODTs) are a patient-friendly dose form that swiftly disintegrants or disperses in the mouth without the necessity of water. This study involved the preparation of nine orodispersible tablet formulations of mebendazole (MBZ), an antihelminthic medication, utilizing several natural superdisintegrants. The solubility and dissolving rate of the therapeutic molecules used in this study were improved by using starch tartrate, sodium starch glycolate and croscarmellose sodium as super disintegrating agents. The formulations were all made utilizing 16-station rotary tablet punching machine and the direct compression method, with a 7.5 mm punch. The next step was to compress the improved mixture into tablets and test their solubility in a controlled laboratory setting. The combination of formulations exhibited favorable flow characteristics, including depth of repose, tapped density, and bulk density. The produced tablets passed all quality control assessment criteria according to I.P. limits and demonstrated good post-compression parameters. Formulation MT3 was determined to be the most effective since it released the most medicine (101.28 percent) in the shortest duration of time (15 minutes) and disintegrated within 30.51 seconds. With a dosage of 37.5 mg, the MT3 formulation includes starch tartrate (ST) as a super disintegrant.

Keywords: Mebendazole, Starch tartrate, Sodium starch glycolate, and Croscarmellose sodium, Orodispersible tablet.

INTRODUCTION

Oral medication delivery is widely accepted, constituting 50-60% of total dose forms. Patient compliance, ease of administration, accuracy of dosage, self-medication, and pain avoidance are some of the benefits of solid dosage forms. However, swallowing challenges are common, especially when water isn't available, such as during motion sickness or coughing bouts. Oro-dispersible tablets break down rapidly when swallowed, catering to those with dysphagia and active lifestyles[1].

ODTs are commonly referred to by different terms, including "fast-melting, fast-dissolving, oral disintegrating, or oro disperse". As per the European Pharmacopoeia, "oro disperse" denotes a tablet that disperses quickly in the mouth before swallowing. Fast dissolving tablets break down swiftly upon tongue contact, enabling the medicine to dissolve or disperse in saliva. The rate of drug dissolution directly impacts absorption speed and the onset of clinical effect[2].

These pills don't need water to dissolve; they do it in a matter of seconds in saliva. The phrase was just accepted by the European Pharmacopoeia "Oro-dispersible tablet" for tablets that dissolve in the mouth in less than 3 minutes. Some ODTs in the market dissolve in under one minute or even 30 seconds. ODTs are made using methods like lyophilization, moulding, and direct compression. While lyophilization and moulding produce tablets that disintegrate rapidly, they may lack durability and be prone to crumbling. In contrast, tablets produced through direct compression exhibit reduced fragility but have a longer disintegration period[3]. There were some work done on orodispersible tablet formulations such as, orlistat[4], ondansetron[5], zolmitriptan[6], pantoprazol[7], Metformin HCl[8], levocetirizine dihydrochloride and Montelukast sodium[9], omeprazole[10], aceclofenac[11], promethazine HCl[12].

Mebendazole is a broad-spectrum anthelmintic. It is white to off-white in colour, having pleasant taste amorphous powder. Nearly insoluble in water, soluble in formic acid, and practically insoluble in ethanol, chloroform, and ether[13]. Starch tartrate is newly explored semi synthetic novel superdisintegrants. Very few work was done hence, we did this work. The current research set out to create and assess the efficacy of various super disintegrants in the production of oral dispersible Mebendazole tablets.

MATERIALS AND METHODS

Chemicals

Mebendazole was obtained as a gift sample from Natco Pharmaceuticals, Hyderabad. Potato starch purchased from Siddharth Starch, Pune. Tartaric acid obtained from Meru Chem Pvt. Ltd., Mumbai. Sodium starch glycolate, croscarmellose sodium, magnesium stearate and microcrystalline cellulose were purchased from Crest Cellulose Pvt. Ltd., Hyderabad. Mannitol, Talc, Sodium saccharin and SLS were purchased from SD Fine-Chem, Mumbai, India. All the used reagents and chemicals were of analytical grade.

Determination of absorption maxima

A UV visible double beam spectrophotometer (EI 1372, Electronics India, Pune, India) was used to obtain the UV spectra of a phosphate buffer with a pH of 6.8 buffer solution containing 10 µg/ml of the MBD has been made. The 200-400 range was used to scan the solution[14].

Construction of Mebendazole calibration curve with phosphate buffer pH 6.8

A solution of 1mg/ml (1000µgm/ml) was prepared by dissolving 100mg of MBZ in 100ml of phosphate buffer at a pH of 6.8. A concentration of 100µgm/ml was achieved by diluting 10 ml of the aforesaid conventional solution (1000µgm/ml) with 100 ml of a buffered phosphate solution (pH 6.8). A 10 ml volumetric flask was used to transfer 0.2, 0.4, 0.6, 0.8-, and 1-ml portions of this stock solution. Then, a buffered phosphate solution with PH 6.8 was added until the volume reached the mark, yielding 2, 4, 6, 8, and 10 µgm/ml concentrations, respectively. The absorption of each concentration was measured at its maximum wavelength, 286 nm[15].

Determination of drug-polymer compatibility by Fourier Transforms Infra-Red (FTIR) Spectroscopy

To determine whether peaks were present or absent, the infrared spectra of the physical mixture and the pure drug were compared. The FTIR spectrometer (Bruker Alpha II FTIR Spectrometer, Mumbai, India) was used to evaluate the compatibility of the pure medication with the excipients. Using a mortar and KBr press, the solid powder sample was ground with an amount of KBr 100 times higher to create the potassium bromide pellets. After that, the finely ground powder was placed within a stainless steel mould and compressed under polished steel anvils at a pressure of about 8 tonnes per square inch. The spectra were acquired across a wave number range of 8000 to 400 cm-1[16].

Synthesis of starch tartrate

A small amount of water (10 mL) was used to dissolve 10 g of starch tartrate synthesis (TA) and 2 g of sodium hypophosphate (SHP) in a beaker. In a 100 mL glass beaker, 10 g of air-dried potato starch (PS) was added to the tartaric acid (TA) solution, and the mixture was rapidly stirred using a glass rod. For 30 minutes, the mixture was dehydrated at 100°C in a forced air oven. At this stage, TA was applied to the starch particles after all surface moisture had been eliminated. The material was allowed to react for five hours after the oven temperature was increased to 120°C. By altering these parameters in multiple earlier experiments, the temperature and reaction time were established[17]. The ST reaction's byproducts were combined with 100 milliliters of water and stirred for 30 minutes at 150 rpm using a mechanical paddle stirrer (Remi Electrotechnik Ltd., India). After passing through whatman filter paper, the slurry was rinsed for 30 minutes with 60, 80, and 100 milliliters of water. After one hour of drying at 60° C in an oven, the yield was calculated and the ST was run through ASTM mesh no. 85[18].

Preparation of tablets

Mebendazole dispersible tablets (100 mg) were formulated using the direct compression method, adding talc and magnesium stearate (6.5 mg) as lubricants, SLS (2.5 mg) as a wetting agent, sodium saccharine (4 mg) as a flavouring agent, mannitol (q.s.) as a diluent, and MCC (20 mg) as a binder. The tablet weight was ascertained to be 250 milligrams. Three tablet series were produced using ST (F1–F3), SSG (F4–F6), and CCS (F7–F9) were used as disintegrants at 5%, 10%, and 15% w/w, respectively. Using a 16-station tablet punching machine, all of the materials were carefully weighed, mixed, and compressed into tablets[19].

Table 1: Formulations of MBZ ODT

Ingredients (mg)	MT1	MT2	MT3	MT4	MT5	MT6	MT7	MT8	MT9
Mebendazole (MBZ)	100	100	100	100	100	100	100	100	100
Starch Tartrate (ST)	12.5	25	37.5						
Sodium Starch Glycolate (SSG)	-	-	-	12.5	25	37.5	-	-	
Croscarmellose Sodium (CCS)	-	-	-	-	-	-	12.5	25	37.5
Microcrystalline cellulose (MCC)	20	20	20	20	20	20	20	20	20
Magnesium Stearate	6.5	6.5	6.5	6.5	6.5	6.5	6.5	6.5	6.5
Talc	6.5	6.5	6.5	6.5	6.5	6.5	6.5	6.5	6.5
SLS	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
Sodium saccharin	4	4	4	4	4	4	4	4	4
Mannitol	98	85.5	73	98	85.5	73	98	85.5	73
Total wt. (mg)	250	250	250	250	250	250	250	250	250

Precompression parameters

Blend Characterization

Twelve different formulations were tested using blend characterization metrics, including bulk and tapped density, compression index, Hausner's ratio and angle of repose.

Post Compression Parameters[20]

Evaluation of uncoated tablets

The pharmacopeial standards were followed to assess each batch of tablet's physical attributes, including the thickness, mass variability, drug content, hardness, friability, and dissolving.

Time of in vitro disintegration[21]

The tablet disintegration test device measured all formulation's disintegration times. Disintegration test tubes held six tablets individually. Tablet disintegration was recorded using a 37 ± 2 °C temperature.

In -vitro dissolution studies[22]

An apparatus (EI -1916, Electronics India, Pune, India) was used for in-vitro release investigations. For every experiment, at a pH of 6.8 of phosphate buffer 500 milliliters was mixed with 50 revolutions per minute of hot water at 37°c. At 2 minute intervals, 5 ml of the dissolving liquid was removed then the absorbance was measured at 286 nm to determine the concentration of mebendazole. At predetermined intervals, 5 ml of each test medium was taken out and swapped out for an equivalent volume of a buffered phosphate solution with a pH of 6.8.

Release Kinetics[23]

The results of the in-vitro diffusion study were utilised to look at the drug release kinetics of mebendazole ODT, including their order and mechanism. The zero order, first order, and Higuchi equations were among the kinetic models that were plotted; the Korsmeyer-Peppas equations were employed to determine the release.

Stability Studies[24, 25, 26]

If a drug wants to be registered in the US, EU, or Japan, it must pass certain stability tests that are laid out in the ICH Guidelines, particularly the "Stability testing of new drug substance and products" (QIA). Stability studies for the present research conducted at 40º C ± 2ºC/75% ± 5% RH for the made a selection and used it for three months.

RESULTS AND DISCUSSION

Mebendazole Standard Calibration curve



Fig 1: Standard graph of Mebendazole

In Figure 1, we can see the Mebendazole curve of calibration in phosphate buffer at pH 6.8. Within a concentration ranged from 0 to 10 µg/ml, it was determined that it was linear at 286 nm, with an R^2 value of 0.998.

Studies on drug-excipient compatibility by FT-IR



Fig 2: FTIR structure of Pure drug Mebendazole



Fig 3: FTIR graph of Optimized formulation

The infrared absorption spectra of Mebendazole and its optimized formulation exhibited characteristic peaks corresponding to CN stretching, NH stretching, and C=O-O stretching. In Mebendazole, CN stretching was observed at 3451 cm^{-1}, NH stretching at 2836 cm^{-1}, and C=O-O stretching at 1699 cm^{-1}. In the optimized formulation, the CN stretching shifted to 2459 cm^{-1}, while NH stretching remained nearly unchanged at 2837 cm^{-1}, and C=O-O stretching slightly shifted to 1694 cm^{-1}. These results showed that there is no interaction between mebendazole and the formulation.

Pre-compression parameters

This information is displayed in Table 2. Angle of repose were determined to be between 20.29±0.41° and 24.32±0.27°. In terms of bulk density, different formulations exhibited values between 0.42±0.04 and 0.48±0.03 (g/cm^2), while tapped densities ranged from 0.57±0.08 to 0.62±0.02 (g/cm^2). The prepared blends have a Carr's index ranging from 14.36±0.24% to 17.23±0.53%. The Hausner's ratio ranged from 1.06±0.07 to 1.14±0.08 for all the formulations. This points to the mixture's enhanced fluidity properties. The results showed that the powder mixtures were suitable for use in tablet production due to their excellent flow characteristics.

Table 2: Pre-compression parameters of mebendazole ODT

Formulations	Bulk Density (g/cm^2)	Tap Density (g/cm^2)	Carr's Index (%)	Hausner ratio	Angle Of Repose(Ɵ)
MT1	0.46±0.01	0.58±0.03	16.17±0.43	1.13±0.05	23.56±0.24
MT2	0.44±0.02	0.60±0.04	15.39±0.28	1.07±0.00	21.26±0.18
MT3	0.42±0.04	0.59±0.06	16.22±0.51	1.14±0.02	20.29±0.41
MT4	0.47±0.03	0.62±0.02	16.14±0.33	1.11±0.04	24.32±0.27
MT5	0.46±0.02	0.60±0.07	15.25±0.69	1.09±0.03	22.41±0.17
MT6	0.44±0.01	0.59±0.05	14.36±0.24	1.06±0.07	21.34±0.38
MT7	0.48±0.03	0.60±0.03	17.23±0.53	1.12±0.11	23.16±0.11
MT8	0.46±0.02	0.57±0.08	16.18±0.41	1.09±0.06	24.27±0.23
MT9	0.45±0.04	0.58±0.11	15.41±0.27	1.14±0.08	22.18±0.47

Parameters after compression

The results, including the percentage deviation are displayed in Table 3. The tablet's weight is around 248.8±3.5 to 252.6±3.4 mg. The results indicated that the tablets' hardness fell within the accepted IP limits, ranging from 2.6±0.3 to 2.8±0.5 kg/cm^2. The tablet's thickness ranged from 3.19±0.11 to 3.57±0.22 mm, according to the results. All of the formulations had an average friability ranging from 0.48±0.03% to 0.69±0.06%, which is below the statutory limit of 1% for IP and suggests that the tablets have acceptable mechanical resilience. The assay investigations indicated that the medication content percentages in each formulation ranged from 97.72±4.28% to 101.17±4.38%.

Table 3: Post-Compression parameters of mebendazole ODT

F code	Weight variation (mg)	Hardness (kg/cm^2)	Thickness (mm)	Friability (%)	Assay (%)
MT1	252.6±3.4	2.8±0.4	3.39±0.12	0.48±0.03	98.41±3.24
MT2	249.3±2.9	2.7±0.3	3.57±0.22	0.52±0.05	101.17±4.38
MT3	250.6±2.1	2.8±0.2	3.19 ±0.11	0.61±0.03	99.99±2.11
MT4	248.8±3.5	2.6±0.4	3.53±0.19	0.58±0.06	100.06±4.32
MT5	251.2±4.1	2.8±0.5	3.28±0.21	0.63±0.03	97.82±2.29
MT6	249.5±2.8	2.7±0.2	3.41±0.13	0.69±0.06	98.61±4.53
MT7	251.7±3.7	2.8±0.4	3.34±0.18	0.57±0.05	98.45±2.47
MT8	249.2±4.5	2.6±0.3	3.26±0.21	0.51±0.02	97.72±4.28
MT9	252.4±2.4	2.7±0.2	3.37±0.25	0.63±0.04	99.36±3.67

In vitro disintegration time

Table 4 displays the results of the in vitro time to disintegration evaluations performed on each batch of tablets. The findings indicated that the duration required for the tablets to dissolve varied between 30.51±1.58 and 57.15±3.72 seconds.

Duration of wetting operations

Table 4 displays the wetting time data for each formulation. The wetting time of prepared tablet formulations was less than 71.83 seconds respectively. The findings demonstrated that the concentration impacted the wetting duration of the super disintegrant. Formulation MT3, which includes ST, had a shorter wetting time compared to the other formulations.

Table 4: Time of disintegration and wetting

F code	Disintegration Time (sec)	Wetting time (sec)
MT1	53.43±2.76	64.14±0.05
MT2	45.62±2.27	56.37±0.07
MT3	30.51±1.58	49.26±0.03
MT4	55.23±2.38	71.83±0.04
MT5	47.47±2.72	63.58±0.07
MT6	42.31±2.69	58.71±0.06
MT7	57.15±3.72	68.33±0.07
MT8	48.28±2.86	61.42±0.03
MT9	43.41±1.37	55.26±0.04

Studies on in vitro dissolution

Utilising a USP dissolving device and the paddle method, 500 ml of 0.68 pH phosphate buffer was utilised for in vitro dissolution tests. The duration of the dissolution experiments was approximately thirty minutes.



Fig 4: Dissolution profile of MBZ formulations prepared with starch tartrate (ST)



Fig 5: Dissolution profile of MBZ formulations prepared with SSG



Fig 6: Dissolution profile of MBZ formulations prepared with CCS

Formulations made with super disintegrant ST demonstrated the fastest drug release rate in 15 minutes, at 101.28 percent (MT3 formulations with a super disintegrant concentration of 37.5 mg), as shown in Figure 4. So, it was determined that the super disintegrant principle may be utilized to create oro-dispersible tablets. For optimization purposes, the MT3 formulation was deemed appropriate.

Using Kinetics of Release Rate for Dissolution

Various models were utilized to examine the drug release kinetics. A number of release of drug models, including first-order, zero-order, Higuchi, and Korsmeyer-Peppas, were fitted to the collected data to examine the echanism underlying the rate kinetics of the dose form.



Fig 7: Zero order release kinetics graph of mebendazole formulations



Fig 8: First order release kinetics graph of mebendazole formulations



Fig 9: Higuchi release kinetics graph of mebendazole formulations



Fig 10: Korsmeyer-Peppas kinetics graph of mebendazole formulations

Figure 7-10 showed the graphical representations of drug released kinetics of MBZ ODT formulations. The R^2 values presented in the first-order kinetic graphs exceeds in contrast to the zero-order kinetic graphs, indicating that the drug release adheres to first-order kinetics. The regression equations of Higuchi plots provide R^2 values exceeding 0.9, showing that drug release adheres to diffusion kinetics. The Korsmeyer-Peppas model is applicable when drug release entails many processes or when the precise mechanisms are indeterminate. The model can additionally ascertain if the release is governed by diffusion. Here "n" is between 0.45 and 0.89, it signifies the medication release is caused via non-fickian diffusion process.

Selection of Best Formulation

Out of nine potential formulations, the one with the best combination of characteristics was selected: rapid drug release, short wetting time, high water absorption ratio, and minimal disintegration time. With a disintegration time of just 30.51 seconds, a drug release rate of 101.28% within 15 minutes, and a wetting time of just 49.26 seconds, Formulation MT3 stood out from the others. According to these considerations, the MT3 formulation is the best one to use.

Stability Studies

A three-month stability investigation was carried out on the MT3 refined compounds in a controlled environment with a 40°C temperature and a 75% relative humidity. Every thirty days, the tablets were tested for a variety of properties, including thickness, hardness, consistency of content, friability, weight change and disintegration time All of the metrics were within the predetermined range, and there was no discernible change from the original data. Measurements were taken every 30 days throughout the three-month in-vitro dissolving research. Exposure to elevated temperatures and controlled humidity levels had no effect on the release patterns.

CONCLUSION

The current study aimed to create mebendazole tablets that dissolve quickly. This study used super disintegrating agents starch tartrate, SSG, and CCS to improve the solubility and dissolving rate of a medication. Every formulation was directly compressed with a 16-millimeter punch on an eight-station rotary tablet punching machine. The combined formulations had good tapped density, bulk density, and angle of repose. FTIR confirmed drug-polymer compatibility. According to FTIR data, the pure drug and excipients have no chemical interaction. Direct compression method was used. Starch tartrate, SSG and CCS were super disintegrant, talc flow promoters, magnesium stearate lubricants, and mannitol sweeteners and diluents were used in this method. Several parameters were evaluated after compression and found satisfactory, including thickness, friability, hardness, wetting time, in vitro drug release, and disintegration. Formulation MT3 was determined to be the most effective since it released the most medicine (101.28 percent) in the shortest duration of time (15 minutes) and disintegrated within 30.51 seconds. With a dosage of 37.5 mg, the MT3 formulation includes starch tartrate (ST) as a super disintegrant.

REFERENCES

[1] Dali shukla, Subhashis Chakraborty, Sanjay Singh, Brahmeshwarn Mishra. Mouth dissolving tablets I: an overview of formulation technology.2009, 77:309- 326.

[2] Tapan kumar, Dulal Krishna, Rana.Formulation aspects in the development of Orodispersible tablets: an overview. International journal of pharmacy and pharmaceutical sciences, 2010: May 07:2(3).

[3] Basawaraj S.patil., K.Dayakar rao., Upendra kulkarni., Hariprasana R.C., 2011, Formulation and evaluation of fast dissolving tablets of Granisetron hydrochloride by direct compression technique, International journal of current plharmaceutical research, Vol. 3, Issue 2.

[4] Syed Wajid, Vamshi Vishnu Yamsani, Suhair S. Alsaleh, Salmeen D. Babelghaith, Suha S. Alsaleh, Mohammed N. Al-Arifi1 Formulation Design and in vitro Evaluation of Orodispersible Tablets of Orlistat by Direct Compression Method Asian Journal of Pharmaceutics Apr-Jun 2017 (Suppl) 11 (2) | S367.

[5] Sravanthi Mulagada, Srinivasa Rao Baratam Design and Evaluation of Ondansetron Fast Disintegrating Tablets Using Natural Polymers and Modified Starches as Super Disintegrants for the Enhancement of Dissolution J Young Pharm, 2017; 9(4):519-524.

[6] T. Balakrishna, S. Vidyadhara, T. E. G. K. Murthy, K. Viswanadh, M. Tejasri Formulation and Evaluation of Orodispersible Tablets of Zolmitriptan Asian Journal of Pharmaceutics • Oct-Dec 2016 (Suppl) • 10 (4) | S683.

[7] Srinivasa, D. S., Charyulu, N. R., Satyanarayana, D. S., & Srilakshmi, D. (2015). Formulation and in vitro comparative evaluation of orodispersible tablets of Pantoprazole. *Research Journal of Pharmacy and Technology*, *8*(10), 1389-1393.

[8] Moris, S., Pananchery, J., & Jain, A. (2015). Formulation and evaluation of metformin HCl mouth dissolving tablet using sublimating agent. *Int. J. Pharma Sci Res*, *6*, 1050-5.

[9] Gupta.M.M. Niraj Gupta., Bhupendra S. Chauhan., 2014, Fast disintegrating combination tablet of taste masked Lewvocetrizine hihydrochloride and Montelukast sodium formulation design, development, and characterization, Research articles Vol.2014, Article ID 568320, 15 pages

[10] Hannan PA, Khan JA, Khan A, Safiullah S. Oral Dispersible System: A New Approach in Drug Delivery System. Indian J Pharm Sci. 2016 Jan-Feb;78(1):2-7.

[11] Bhardwaj, S., Jain, V., Jat, R. C., Mangal, A., & Jain, S. (2010). Formulation and evaluation of fast dissolving tablet of aceclofenac. *International journal of drug delivery*, *2*(1).

[12] Mahamuni, S. B., Shahi, S. R., Shinde, N. V., & Agrawal, G. R. (2009). Formulation and evaluation of fast dissolving tablets of promethazine hcl with masked bitter taste. *Int. J. Pharm. R. Dev*, *7*, 1-1.
[13] National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 4030, Mebendazole. Retrieved February 5, 2025 from https://pubchem.ncbi.nlm.nih.gov/compound/Mebendazole.
[14] Srinivasa Sastry D, Narayana Charyulu R, Satyanarayana D S, Srilakshmi D Formulation and Evaluation of Orodispersible Tablets of an Antiulcer Agent RJPT Volume No.: 10 Issue No.: 3 Year: 2017 Pages: 747-750
[15] https://patents.google.com/patent/RU2524638C2/en
[16] Errolla Mahesh, G. B. Kiran Kumar, Mohammed G Ahmed, Kiran Kumar P, Formulation and evaluation of montelukast sodium fast dissolving tablets. Asian journal of biomedical and pharmaceutical sciences 2012; 2(14): 75-82.
[17] Wing, R. E., Starch citrate: Preparation and ion exchange properties. Starch/Stärke 1996, 48, 275–279.
[18] Salam, A., Pawlak, J. J., Venditti, R. A., El-Tahlawy, K., Biomacromolecules 2010, 11, 1453–1459.
[19] Assaleh FH, Katakam P, Botcha R, Chandu BR, Adiki SK. Synthesis and characterisation of starch tartrate and its application as novel disintegrant in telmisartan tablets. Starke [Internet]. 2014;66(3–4):409–17. Available from: http://dx.doi.org/10.1002/star.201300136
[20] Kuchekar BS, Badhan AC, Mahajan HS. Mouth dissolving tablets of Salbutamol sulphate: A novel drug delivery system. Indian Drugs 2004; 41: 592-8.
[21] Koizumi K, Watanabe Y, Morita K, Utoguchi N, Matsumoto M. New method of preparing high-porosity rapidly saliva soluble compressed tablets using mannitol with camphor, a subliming material. International Journal of Pharmaceutics 1997; 152 (1): 127- 31
[22] Andreas Gryczke, Silke Schminke, Mohammed maniruzzaman, julien Beck, Development and evaluation of orally disintegrating tablets containg ibuprofen granules prepared by hot melt extrusion. Colloids and surfaces B: Biointerfaces 2011; 86: 275-284.
[23] V. Juyal1, M. Chaudhary, P. Kumar, G. Gnanarajan, P. K. Yadav: Method development and its validation for simultaneous estimation of atorvastatin and amlodipine in combination in tablet dosage form by UV spectroscopy, using multi-component mode of analysis, J Pharma Res.,; Dec 2008; 1(2); 182 - 187.
[24] Patel DM, Patel MM. Optimization of fast dissolving etorocoxib tablets prepared by sublimation technique. Indian J Pharm Sci. 2008; 70(1): 71–76.
[25] International Conference on Harmonization (ICH), Harmonized Tripartite guideline For stability testing of existing active substances and related finished products Q1A (R2) 2004 Mar.
[26] International Conference on Harmonization (ICH), Harmonized Tripartite guideline for stability testing of new drugs substances and products Q1A (R2) 2003 Aug.